Avalo Therapeutics, INC. (AVTX) — SEC Filings

Q: What are the key financial highlights for Avalo Therapeutics, INC.?

Key financial highlights for Avalo Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Avalo Therapeutics, INC.?

Key executives at Avalo Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Avalo Therapeutics, INC. stock?

Risk factors for Avalo Therapeutics, INC. (AVTX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Avalo Therapeutics, INC.?

Forward-looking statements and predictions from Avalo Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Avalo Therapeutics, INC.. Recent 8-K filing on Dec 2, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Avalo Therapeutics, INC. on SEC EDGAR

Overview

Avalo Therapeutics, INC. (AVTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 2, 2025: Avalo Therapeutics, Inc. filed an 8-K on December 2, 2025, reporting an "Other Events" item. The company, formerly known as Cerecor Inc. until November 2, 2011, is incorporated in Delaware and headquartered in Wayne, Pennsylvania. This filing does not contain specific financial figures or details ab

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Avalo Therapeutics, INC. is neutral.

Filing Type Overview

Avalo Therapeutics, INC. (AVTX) has filed 25 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 8 SC 13G, 1 10-Q/A, 2 8-K/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

Avalo Therapeutics Files 8-K — 8-K · Dec 2, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on December 2, 2025, reporting an "Other Events" item. The company, formerly known as Cerecor Inc. until November 2, 2011,
Avalo's Losses Mount Amid Soaring R&D Costs, Cash Dwindles — 10-Q · Nov 6, 2025 Risk: high
Avalo Therapeutics, Inc. (AVTX) reported a significant net loss of $64.5 million for the nine months ended September 30, 2025, a substantial increase from the n
Avalo Therapeutics Files 8-K — 8-K · Oct 29, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting other events and financial statements. The company, formerly known as Cerecor Inc. until No
Avalo Therapeutics Files 8-K — 8-K · Oct 10, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on October 10, 2025, reporting other events and financial statements. The company, formerly known as Cerecor Inc. until No
Avalo Therapeutics Reports Director/Officer Changes & More — 8-K · Oct 1, 2025 Risk: medium
Avalo Therapeutics, Inc. filed an 8-K on October 1, 2025, reporting on events as of September 29, 2025. The filing covers the departure of directors or certain
Avalo Therapeutics Files 8-K on Officer/Director Changes — 8-K · Sep 22, 2025 Risk: medium
Avalo Therapeutics, Inc. filed an 8-K on September 22, 2025, reporting events as of September 16, 2025. The filing covers the departure of directors or certain
Avalo Therapeutics Reports Zero Revenue, Deepening Losses in Q2 — 10-Q · Aug 7, 2025 Risk: high
Avalo Therapeutics, Inc. (AVTX) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net
Avalo Therapeutics Files 8-K — 8-K · Jun 20, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific d
Avalo Therapeutics Announces Board Changes and Executive Compensation Updates — 8-K · Jun 18, 2025 Risk: medium
Avalo Therapeutics, Inc. announced on June 17, 2025, a series of significant corporate actions. These include the departure of certain directors and officers, t
Avalo Therapeutics Files 8-K on Security Holder Vote — 8-K · Jun 17, 2025 Risk: medium
On June 17, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. N
Avalo Therapeutics Announces Material Agreements — 8-K · Jun 5, 2025 Risk: medium
On June 3, 2025, Avalo Therapeutics, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The filing details t
Avalo Therapeutics Files 8-K — 8-K · Jun 4, 2025 Risk: low
On June 4, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information related to "Other Events" and "Fin
Avalo Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
Avalo Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Cerecor Inc., is based in Wayne, PA. The filing det
Avalo Therapeutics Files 8-K — 8-K · May 8, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Cerecor I
Avalo Therapeutics Files 2025 Proxy Statement — DEF 14A · May 1, 2025 Risk: low
Avalo Therapeutics, Inc. (AVTX) filed a DEF 14A on May 1, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and corp
Avalo Therapeutics Files 8-K on Director/Officer Changes — 8-K · Mar 26, 2025 Risk: low
On March 25, 2025, Avalo Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
Avalo Therapeutics Files 2024 10-K — 10-K · Mar 20, 2025 Risk: medium
Avalo Therapeutics, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Cerecor In
Avalo Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
On January 13, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material ev
Avalo Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jan 2, 2025 Risk: medium
On January 1, 2025, Avalo Therapeutics, Inc. (formerly Cerecor Inc.) filed an 8-K report. The filing indicates changes related to the departure of directors or
Avalo Therapeutics Files 8-K — 8-K · Dec 5, 2024 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on December 5, 2024, reporting other events and financial statements. The company, formerly known as Cerecor Inc., is inco
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 14, 2024
Avalo Therapeutics Files 8-K — 8-K · Nov 12, 2024 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on November 12, 2024, reporting other events and financial statements. The company, formerly known as Cerecor Inc., is inc
Avalo Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
Avalo Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Cerecor Inc., reported its financial status. Ke
SC 13G/A Filing — SC 13G/A · Nov 7, 2024
Avalo Therapeutics Files 8-K — 8-K · Oct 8, 2024 Risk: low
On October 8, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
SC 13G Filing — SC 13G · Oct 7, 2024
Avalo Therapeutics Files 8-K Report — 8-K · Sep 9, 2024 Risk: low
On September 9, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
Avalo Therapeutics Appoints New Chief Medical Officer — 8-K · Sep 4, 2024 Risk: medium
On September 3, 2024, Avalo Therapeutics, Inc. (AVTX) announced the appointment of Dr. David E.I. Cromwell as Chief Medical Officer. Dr. Cromwell brings extensi
SC 13G Filing — SC 13G · Aug 23, 2024
SC 13G Filing — SC 13G · Aug 23, 2024
SC 13G Filing — SC 13G · Aug 23, 2024
Avalo Therapeutics to be Acquired by Ares Acquisition Corp. — 8-K · Aug 14, 2024 Risk: medium
Avalo Therapeutics, Inc. (AVTX) announced on August 13, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Ares Acquisition
Avalo Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
Avalo Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Cerecor Inc., reported financial results and operati
Avalo Therapeutics Merges with LumiraDx, Renamed LumiraDx — 8-K · Jul 30, 2024 Risk: medium
On July 29, 2024, Avalo Therapeutics, Inc. announced the closing of its previously disclosed merger with LumiraDx Limited. The merger was approved by Avalo's st
Avalo Therapeutics Board Changes — 8-K · Jul 16, 2024 Risk: medium
Avalo Therapeutics, Inc. announced on July 15, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Rothberg has resigned from his position a
Avalo Therapeutics Files Amended Q1 2024 Report — 10-Q/A · Jul 11, 2024 Risk: low
Avalo Therapeutics, Inc. filed an amended 10-Q for the period ending March 31, 2024. The filing, dated July 11, 2024, provides updated financial information. Th
Avalo Therapeutics Files 8-K for Financials and Exhibits — 8-K · Jul 9, 2024 Risk: low
On July 9, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, with no other spec
Avalo Therapeutics Files 2024 Proxy Statement — DEF 14A · Jun 27, 2024 Risk: low
Avalo Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on June 27, 2024, for its annual meeting scheduled for August 13, 2024. The filing conce
Avalo Therapeutics Files Amendment to 8-K — 8-K/A · Jun 24, 2024 Risk: low
Avalo Therapeutics, Inc. filed an amendment (No. 2) to its Form 8-K on March 27, 2024, originally filed on March 28, 2024. This amendment primarily concerns the
Avalo Therapeutics Files Amendment to 8-K — 8-K/A · Jun 3, 2024 Risk: low
Avalo Therapeutics, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on March 27, 2024, which was filed on March 28, 2024. This amendment pertains to I
Avalo Therapeutics Faces Nasdaq Delisting — 8-K · May 23, 2024 Risk: high
Avalo Therapeutics, Inc. (AVTX) received a notice on May 20, 2024, indicating it failed to meet the continued listing standards of the Nasdaq Capital Market. Th
SC 13G Filing — SC 13G · May 13, 2024
Avalo Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
Avalo Therapeutics, Inc. (AVTX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Avalo Therapeutics, Inc. filed a 10-Q report for the quarterly per
SC 13G Filing — SC 13G · Apr 23, 2024
SC 13G Filing — SC 13G · Apr 5, 2024
Avalo Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: medium
Avalo Therapeutics, Inc. (AVTX) filed a Annual Report (10-K) with the SEC on March 29, 2024. Avalo Therapeutics, Inc. filed its annual report on Form 10-K for t
Avalo Therapeutics Reports Material Agreement, Delisting Notice — 8-K · Mar 28, 2024 Risk: high
Avalo Therapeutics, Inc. announced on March 27, 2024, that it entered into a Material Definitive Agreement. The company also provided updates on the completion
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024

Risk Profile

Risk Assessment: Of AVTX's 38 recent filings, 4 were flagged as high-risk, 15 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Avalo Therapeutics, INC.'s most recent 10-Q filing (Nov 6, 2025):

Revenue: $0
Net Income: -$64.5M
EPS: N/A
Debt-to-Equity: 0.37
Cash Position: $27.0M
Operating Margin: N/A
Total Assets: $125.1M
Total Debt: $33.6M

Key Executives

Garry Neil, M.D.
Michael Cola
Dr. David E.I. Cromwell
Dr. Jonathan M. Rothberg

Industry Context

Avalo Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the potential for substantial returns upon successful drug commercialization. Companies like Avalo often rely on external funding to advance their pipelines through clinical trials.

Top Tags

financials (10) · corporate-governance (7) · 8-K (5) · filing (5) · 10-Q (5) · sec-filing (4) · regulatory-filing (3) · 8-k (3) · Pharmaceuticals (3) · executive-compensation (3)

Key Numbers

Net Loss: $64.5M — for the nine months ended September 30, 2025, compared to $0.21M net income in 2024
Cash and Cash Equivalents: $27.0M — as of September 30, 2025, down from $134.5M at December 31, 2024
Short-term Investments: $84.7M — as of September 30, 2025, newly acquired
Research and Development Expenses: $36.8M — for the nine months ended September 30, 2025, up from $16.3M in 2024
Change in Fair Value of Derivative Liability: $14.7M — negative impact for the nine months ended September 30, 2025
Total Liabilities: $33.6M — as of September 30, 2025, up from $17.7M at December 31, 2024
Non-current Derivative Liability: $23.2M — as of September 30, 2025, up from $8.1M at December 31, 2024
Net Cash Used in Operating Activities: $37.2M — for the nine months ended September 30, 2025
Common Shares Outstanding: 18,133,968 — as of November 3, 2025
SEC File Number: 001-37590 — Identifies the company's filing with the SEC
IRS Employer Identification No.: 45-0705648 — Company's tax identification number
Revenue: $0 — for the three and six months ended June 30, 2025, indicating no commercial products
Period End Date: 2025-06-30 — the reporting period for this 10-Q filing
Central Index Key (CIK): 0001534120 — unique identifier for Avalo Therapeutics, Inc. with the SEC
Reporting Period End Date: 20250331 — Indicates the end of the fiscal quarter covered by the report.

Related Companies

AVLO · LMDX

Frequently Asked Questions

What are the latest SEC filings for Avalo Therapeutics, INC. (AVTX)?

Avalo Therapeutics, INC. has 50 recent SEC filings from Feb 2024 to Dec 2025, including 25 8-K, 8 SC 13G, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AVTX filings?

Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Avalo Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Avalo Therapeutics, INC. (AVTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Avalo Therapeutics, INC.?

Key financial highlights from Avalo Therapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AVTX?

The investment thesis for AVTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Avalo Therapeutics, INC.?

Key executives identified across Avalo Therapeutics, INC.'s filings include Garry Neil, M.D., Michael Cola, Dr. David E.I. Cromwell, Dr. Jonathan M. Rothberg.

What are the main risk factors for Avalo Therapeutics, INC. stock?

Of AVTX's 38 assessed filings, 4 were flagged high-risk, 15 medium-risk, and 19 low-risk.

What are recent predictions and forward guidance from Avalo Therapeutics, INC.?

Forward guidance and predictions for Avalo Therapeutics, INC. are extracted from SEC filings as they are enriched.